

Cite this: *Chem. Sci.*, 2019, 10, 3654

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Ultraspecific live imaging of the dynamics of zebrafish neutrophil granules by a histopermeable fluorogenic benzochalcone probe†

Emma Colucci-Guyon,<sup>1</sup> Ariane S. Batista,<sup>1,2</sup> Suellen D. S. Oliveira,<sup>1,3</sup> Magali Blaud,<sup>4</sup> Ismael C. Belletini,<sup>5</sup> Benoit S. Marteyn,<sup>6</sup> Karine Leblanc,<sup>7</sup> Philippe Herbomel<sup>1,8</sup> and Romain Duval<sup>1,9</sup>\*

Neutrophil granules (NGs) are key components of the innate immune response and mark the development of neutrophilic granulocytes in mammals. However, there has been no specific fluorescent vital stain up to now to monitor their dynamics within a whole live organism. We rationally designed a benzochalcone fluorescent probe (**HAB**) featuring high tissue permeability and optimal photophysics such as elevated quantum yield, pronounced solvatochromism and target-induced fluorogenesis. Phenotypic screening identified **HAB** as the first cell- and organelle-specific small-molecule fluorescent tracer of NGs in live zebrafish larvae, with no labeling of other cell types or organelles. **HAB** staining was independent of the state of neutrophil activation, labeling NGs of both resting and phagocytically active neutrophils with equal specificity. By high-resolution live imaging, we documented the dynamics of **HAB**-stained NGs during phagocytosis. Upon zymosan injection, labeled NGs were rapidly recruited to the forming phagosomes. Despite being a reversible ligand, **HAB** could not be displaced by high concentrations of pharmacologically relevant competing chalcones, indicating that this specific labeling was the result of the **HAB**'s precise physicochemical signature rather than a general feature of chalcones. However, one of the competitors was discovered as a promising interstitial fluorescent tracer illuminating zebrafish histology, similarly to BODIPY-ceramide. As a yellow-emitting histopermeable vital stain, **HAB** functionally and spectrally complements most genetically incorporated fluorescent tags commonly used in live zebrafish biology, holding promise for the study of neutrophil-dependent responses relevant to human physiopathology such as developmental defects, inflammation and infection. Furthermore, **HAB** intensely labeled isolated live human neutrophils at the level of granulated subcellular structures consistent with human NGs, suggesting that the labeling of NGs by **HAB** is not restricted to the zebrafish model but also relevant to mammalian systems.

Received 14th December 2018  
Accepted 12th February 2019

DOI: 10.1039/c8sc05593a

rsc.li/chemical-science

The zebrafish (*Danio rerio*), a precious vertebrate model in developmental biology, has recently emerged as a powerful non-mammalian model to study the development and the function of the immune system and to address the host–pathogen interaction in the context of an entire live organism. The small size and the natural translucency of the zebrafish embryo and

swimming larva make it possible to follow leukocyte deployment, behavior and functions *in vivo* at high resolution throughout the organism.<sup>1,2</sup> Maturation and deployment of myeloid cell lineages have been characterized for more than a decade. Zebrafish possesses a multi-lineage myeloid compartment with two types of granulocytes (heterophils/

<sup>1</sup>Institut Pasteur, Unité Macrophages et Développement de l'Immunité, Paris, 75015, France. E-mail: emma.colucci@pasteur.fr

<sup>2</sup>CNRS, UMR 3738, Paris, France

<sup>3</sup>Nanotechnology Engineering Program, Instituto Alberto Luiz Coimbra de Pós-Graduação e Pesquisa de Engenharia – COPPE, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-972, Brazil

<sup>4</sup>Department of Anesthesiology, University of Illinois, Chicago, 60612, USA

<sup>5</sup>LCRB, CNRS, Université Paris 5, Sorbonne Paris Cité, Paris, 75006, France

<sup>7</sup>Departamento de Ciências Exatas e Educação, Universidade Federal de Santa Catarina, Blumenau, 89036-256, Brazil

<sup>8</sup>Institut Pasteur, Unité de Pathogénie Microbienne Moléculaire, Paris, 75015, France

<sup>9</sup>INSERM, UMR 786, Paris, France

<sup>6</sup>BioCIS, CNRS, Université Paris-Sud 11, Châtenay-Malabry, 92290, France

<sup>7</sup>MERIT, IRD, Université Paris 5, Sorbonne Paris Cité, Paris, 75006, France. E-mail: romain.duval@ird.fr

† Electronic supplementary information (ESI) available: Detailed experimental procedures regarding compound synthesis, structural and spectral characterization, pK<sub>a</sub> prediction, bioimaging experiments, staining dynamics of **HAB** in 72 hpf zebrafish larvae (Videos) and complementary figures. See DOI: 10.1039/c8sc05593a

‡ These co-authors contributed equally to this work.



neutrophils and eosinophils), and monocytes/macrophages, each with characteristic morphological and histochemical features. Macrophages appear during the first day of zebrafish development, followed by neutrophils that arise a day later, both leukocytes representing together a first, efficient immune system for the developing fish.<sup>3–5</sup> Zebrafish neutrophils are morphologically and functionally similar to their mammalian counterpart. They are equipped with granules containing microbicidal compounds, they engulf and kill invading microorganisms, and have been extensively studied for their key roles in innate immunity and inflammation. The availability of transgenic fish lines expressing GFP or other fluorescent proteins under the control of specific neutrophil promoters allows the live imaging of neutrophil behavior in the context of the entire organism.<sup>6,7</sup> Although several small-molecule tracers of neutrophil granules have been described (*e.g.*, quinacrine, LysoTrackerRed®, fluorescent tyramide conjugates or Sudan Black staining for endogenous peroxidase-containing granules), they are either non-specific in terms of labeled organelles or limited to fixed samples and therefore unusable as vital stains for live animal imaging.<sup>5,8,9</sup>

In our development of fluorescent organic dyes for biological applications, we searched for small size, non-canonical fluorophores with novel structure–fluorescence relationships (SFRs),<sup>10</sup> and identified the chalcone scaffold as such a motif. Chalcones (1,3-diphenyl-2-propen-1-ones) have been investigated as fluorescent chemosensors for several analytical applications,<sup>11–13</sup> and as pharmacological probes in a few cases.<sup>14–17</sup> However, their development as fluorotracers has remained hampered by suboptimal photophysics such as minute to modest quantum yields,<sup>11–13</sup> by poor cytopermeabilities limiting biological labeling to cell surfaces<sup>14,15</sup> or extracellular deposits,<sup>17</sup> by substantial non-specific labeling,<sup>16</sup> and by weakly documented SFRs.<sup>14–16,18</sup> These constitute severe drawbacks for potential fluorophores that are otherwise compact, easy to synthesize and also spectrally tractable by chemical modulation. They define the challenges to be addressed in the design of an optimal chalcone probe for biological studies.

## Results

### Probe synthesis and fluorescence structure–activity relationships

Chalcone itself is intrinsically non-fluorescent. Towards emissive chalcones possessing optimal photophysics and high cytopermeability for live-cell and live-animal imaging, we rationally delineated minimal structural modifications of the 1,3-diarylpropenone system (Fig. 1). Organic fluorophores are classically composed of push–pull moieties connected by means of an extended conjugation, allowing efficient excited state intramolecular charge transfers (ICTs).<sup>10</sup> Accordingly, an electron donating aromatic ring (B) would be conjugated to the enone system, with the arylcarbonyl (A) acting as the electron-withdrawing moiety in the chalcone system (Fig. 1). The electron donating aryl was chosen as a naphthyl group, known to increase fluorescence intensity while exerting bathochromic effects with respect to the phenyl group.<sup>10,19</sup> This shift is useful for

microscopic imaging as it diminishes light scattering, cellular auto-fluorescence and phototoxicity.<sup>20,21</sup> In addition, the more lipophilic naphthyl nucleus would dramatically increase the ability of a given probe to penetrate cells and organelles. We finally settled on a pivotal primary amino group as the electron donating substituent, having in mind its useful transformation to the azide for fluorogenic photolabeling strategies of cells or proteomes.<sup>22</sup> Accordingly, we targeted the 3-aminobenzochalcone core as the optimal fluorophore in this series, featuring the most extended captodative system, and expected to display maximal fluorescence intensity and bathochromism (Fig. 1).

These 3-aminobenzochalcones were obtained by reduction of the corresponding nitro intermediates, accessed by Claisen–Schmidt condensation of various acetophenones with 8-nitro-2-naphthaldehyde **2**. Starting from  $\beta$ -naphthaldehyde **1**,<sup>23</sup> a small library of benzochalcones **3–8** was thus obtained where the electron density of the acetophenyl part was tuned from severely deficient ( $R = 4\text{-CF}_3$ ) to strongly enriched ( $R = 4\text{-OH}$ ) (Fig. 2A). Two close analogues were synthesized for the physicochemical standardization of this new series: (i) 5-aminobenzochalcone **12** is a regioisomer of 3-aminobenzochalcone **8**, possessing a less extended captodative system as a pseudo-*para* conjugation; (ii) 2-aminochalcone **14** is the exact chalcone congener of 3-aminobenzochalcone **6**, and should permit to quantify the influence of the naphthyl ring both in terms of fluorescence and lipophilicity. Compound **12** was obtained from  $\beta$ -methyl-naphthalene **9** upon regioselective nitration<sup>24</sup> and then methyl oxidation. The obtained 6-nitro-2-naphthaldehyde **11** was converted to 5-aminobenzochalcone **12** by a “one-pot” condensation–reduction as for aminochalcones **3–8**. 2-Amino-chalcone **14** was obtained from 2-nitrobenzaldehyde **13**




Fig. 1 Stepwise design of a minimal cytopermeable chalcone fluorophore (EWG, electron withdrawing group; EDG, electron donating group; R, any substituent).



following the same strategy (Fig. 2A) (see ESI† for all synthetic procedures).

3-Aminobenzochalcones were indeed fluorescent compounds, in agreement with our design of this novel fluorophore. However, while electron-withdrawing acetophenyl rings were expected to yield the most fluorescent compounds (Fig. 1), the strongest fluorescence was associated with the electron donating 4'-hydroxy group (cpd **8**), while a 4'-trifluoromethyl group (cpd **3**) induced a much weaker fluorescence (Fig. 2B). The spectral properties of these fluorophores are given in Table S1 in the ESI† and depicted in Fig. 3. 3-Aminobenzochalcones optimally display high Stokes shifts predicting an absence of internal quenching, with emission in the green-yellow region of the visible spectrum in toluene. As anticipated from Fig. 2B, 4'-hydroxy-3-aminobenzochalcone **8** (**HAB**), with a 54.0% quantum yield, was significantly more fluorescent than its non-substituted congener **6**. This relation is validated by the further weaker quantum yield of 38.2% of the *p*-trifluoromethyl derivative **3**. Importantly, the favourable influence of a strongly electron donating A ring called for revision of fluorophore representation in the chalcone series, with permanent enolization of the carbonyl occurring in an extended conjugation pattern similarly to the prototypical fluorescein or rhodamine fluorophores (Fig. 3). Further, **HAB** was far more fluorescent than its 5-amino regioisomer **12** with a *ca.* 20-fold higher quantum yield.

This enormous difference in quantum yield between **HAB** and **12** cannot be explained solely by conjugation patterns: **HAB** features rotational hindrance of the 3-amino group (having *peri*

relationships with H-2), a phenomenon absent in the 5-amino regioisomer **12**.<sup>25,26</sup> As a result, **HAB** should be less susceptible to non-radiative de-excitation than **12**, thereby favouring fluorescence transitions. Comparing the isoelectronic compounds 3-aminobenzochalcone **6** and 2-aminochalcone **14** showed as expected that the substitution of the (B) phenyl group for a naphthyl in **6** resulted in much stronger fluorescent emission. Compound **6** thus possesses a quantum yield over eight-fold higher than **14**, the latter also displaying cyan emission and a smaller Stokes shift. Noteworthy for future biological studies, the quantum yield of 54.0% for the most fluorescent aminobenzochalcone **HAB** is higher than those of dansylamides (*e.g.*, DPP)<sup>27</sup> and indocyanines (*e.g.*, ICG),<sup>28</sup> prototypical fluorescent probes for live-cell and live-animal imaging, respectively, and is also, to our knowledge, the highest described to date in the chalcone series (see Table S1 in the ESI†).

### Solvatochromic behavior

**HAB** and its non-substituted analogue **6** exhibited pronounced solvatochromism ( $\Delta_{\max}\lambda_{\text{em}} \sim 140$  nm), being virtually non-fluorescent in water, biological buffers and alcohols, moderately emissive in polar aprotic solvents (*e.g.*, ethyl acetate) and strongly fluorescent in non-polar solvents (*e.g.*, toluene), with the exception of alkanes. While **6** was significantly fluorescent in *n*-hexane and *n*-octane, its 4'-hydroxy derivative **HAB** proved undetectable in these solvents, and showed only weak fluorescence in *n*-alkanols used to model biological lipids (*e.g.*, *n*-heptanol) (Fig. 4a and b). Although the lack of fluorescence of




Fig. 2 Synthesis of representative compounds in the 3-aminobenzochalcone, 5-amino-2-aminobenzochalcone and 2-aminochalcone series and SFRs in the 3-aminobenzochalcone series. (A) Reagents and conditions: (a) HNO<sub>3</sub> (40 equiv.), H<sub>2</sub>SO<sub>4</sub> (1.5 equiv.), AcOH, r. t., 13% **2**; (b) substituted acetophenone (1 equiv.), NaOH (0.75–2 equiv.), EtOH, r. t.; (c) SnCl<sub>2</sub> (5–10 equiv.) or cat. Pd–C (10%), H<sub>2</sub>, AcOH, r. t., 38% **3**, 31% **4**, 26% **5**, 37% **6**, 18% **7**, 69% **8**; (d) HNO<sub>3</sub> (1.25 equiv.), Ac<sub>2</sub>O, r. t., 11% **10**; (e) SeO<sub>2</sub> (2 equiv.), neat, 150 °C, 28% **11** (45% based on conversion); (f) 4-hydroxyacetophenone (1 equiv.), NaOH (2 equiv.), EtOH, r. t.; (g) Fe (10 equiv.), AcOH, reflux, 56% **12**; (h) acetophenone (1 equiv.), NaOH (0.75 equiv.), EtOH, r. t.; (i) Pd–C (10%), H<sub>2</sub>, AcOH, r. t., 12% **14** (yields of chalcones indicated for two-step, "one-pot" reactions). See ESI† for all synthetic procedures. (B) Semi-quantitative emission spectra of 3-aminobenzochalcones **3–8** (50 μM) in toluene at 20 °C.






Fig. 3 SFRs and  $\log D_{7.4}$  values at 20 °C in the 3-aminobenzochalcone, 5-aminobenzochalcone and 2-aminobenzochalcone series (colours indicative of fluorescence emissions).

**HAB** in biological buffers may be perceived as a limitation for imaging studies, it must be realized that the binding of **HAB** to the amphipathic affinity sites of protein targets should result in a 4–500 fold fluorescence turn-on (FTO) according to Fig. 4b.<sup>10</sup> As a proof-of-principle, bovine serum albumin (BSA) quenched **HAB**'s weak blue fluorescence ( $\lambda_{ex} = 360 \text{ nm}$ ,  $\lambda_{em} = 445 \text{ nm}$ ) in a dose–response manner while inducing the formation of a strongly yellow-emitting **HAB**–protein fluorescent complex ( $\lambda_{ex} = 420 \text{ nm}$ ,  $\lambda_{em} = 578 \text{ nm}$ ) (Fig. 4e and f). A FTO of 21.5 (excitation at 420 nm, at a BSA concentration of 10 mg ml<sup>-1</sup>) was observed upon binding of **HAB** to the protein (Fig. 4f), associated with an important bathochromic shift of its fluorescence spectrum ( $\Delta\lambda_{ex} = 60 \text{ nm}$ ,  $\Delta\lambda_{em} = 133 \text{ nm}$ ) which was similar to that obtained in the polar aprotic solvent DMF (Fig. 4d–f). This behaviour is opposite to that of chalcones binding the physiological sites of BSA and displaying slight hypsochromic shifts and quenching effects indicative of an apolar environment,<sup>18</sup> suggesting that **HAB** binds non-conventional BSA sites. Overall, **HAB** should feature a high signal-to-noise ratio and elevated pharmacological sensitivity, showing low or negligible fluorescence in compartments such as the extracellular medium, the cytosol and the membranes in free form, and high fluorescence when target-bound (“in-target” fluorogenesis). Moreover, its absence of fluorescence in water or buffers has the potential to greatly simplify and time-optimize the staining protocols, with suppression of tedious washing steps and diffusion liabilities following dye administration.

### Cytopermeability evaluation

Lipophilicity is a key physicochemical parameter affecting cellular penetration and subcellular distribution *in vitro*, as well


as pharmacokinetics *in vivo*.<sup>29</sup> We measured the partition coefficients of key benzochalcones compared to reference chalcones using *n*-octanol and pH 7.4 phosphate buffered saline (PBS), to draw structure–cytopermeability relationships in this novel series (Fig. 3). As expected, the favorable influence of a naphthyl vs. a phenyl ring regarding fluorescence was also exerted in terms of lipophilicity, as 3-aminobenzochalcone **6** and **HAB** possessed  $\log D_{7.4}$  values significantly higher than that of mere 2-aminobenzochalcone **14**. In particular, **6** was almost three times more lipophilic than its exact 2-aminobenzochalcone congener **14**. On the other hand, the presence of a 4'-hydroxy group on **HAB** made it 2-fold more hydrophilic than its 4'-deshydroxy congener **6**. Further, **HAB** was three to eleven times more lipophilic than 3-nitrochalcone **15** and natural flavokawain A **16** chosen as representative biologically active chalcones<sup>30,31</sup> (Fig. 3). Overall, the neat amphipathicity ( $\log D_{7.4}$  between 1.5 and 2.5), and neutrality as well as small molecular weight (289.3 Da) of **HAB**<sup>32</sup> predict an optimal histopermeability for this compound, which thus could behave as a fast-acting fluorescent probe *in vivo*.

### HAB labels specific cells in live zebrafish embryos and swimming larvae

**HAB**, the most fluorescent, solvatochromic and histopermeable derivative obtained, was tested in representative transparent animal models. We chose the nematode *Caenorhabditis elegans* and the zebrafish *Danio rerio* to study the cell and organelle distribution of **HAB** in complete live organisms and assess its biological specificity. **HAB** could not be microscopically visualized in *C. elegans* due to excessive autofluorescence of the nematode (data not shown). On the other hand, **HAB** displayed a unique labeling pattern in zebrafish that deserved in-







**Fig. 4** HAB shows strong solvatochromism and protein-dependent fluorogenesis. (a and b) Semi-quantitative emission spectra of 3-amino-benzochalcone 6 (a) and HAB (b) in various solvents (50  $\mu\text{M}$ ). (A)  $\text{H}_2\text{O}$ ; (B) Tris buffer 10 mM, pH 7, NaCl 100 mM,  $\text{MgCl}_2$  5 mM; (C) AcOH; (D) DMSO; (E) MeCN; (H)  $\text{CHCl}_3$ ; (I) AcOEt; (J) 1,4-dioxane; (K) benzene; (L) toluene. Dissimilar solvent lettering between the figures is (F) *n*-hexane; (G) *n*-octane (a) and (F) *n*-butanol; (G) *n*-heptanol (b). (c and d) Normalized excitation spectra (purple lines) and fluorescence emission spectra (blue or orange lines) of HAB (50  $\mu\text{M}$ ) in TRIS buffer pH 7.0 (Tris·HCl 10 mM, NaCl 100 mM,  $\text{MgCl}_2$  5 mM) (c) or DMF (d). (e) Fluorescence emission spectra of HAB (50  $\mu\text{M}$ ) titrated with BSA (0 to 1  $\text{mg mL}^{-1}$ ) in TRIS buffer with an excitation wavelength of 360 nm. (f) Fluorescence emission spectra of HAB (50  $\mu\text{M}$ ) titrated with BSA (1 to 10  $\text{mg mL}^{-1}$ ) in TRIS buffer with an excitation wavelength of 420 nm. Arrows indicate the decrease or increase in fluorescence following the addition of BSA. UVA-irradiated cuvettes in the corresponding conditions are shown as insets in (c), (d) and (f).

depth investigation. When HAB was incubated at 10  $\mu\text{M}$  for 60 min on live zebrafish embryos and swimming larvae ranging from 24 hours post-fertilization (hpf) to 72 hpf, fluorescence emission was detected mainly in the 550–650 nm window following excitation at 488 nm, indicative of a non-aqueous environment (see Fig. 4b for the solvatochromic properties of HAB, and Fig. S2 in the ESI† for the emission spectrum of HAB *in vivo*). Since the fluo-labeling was maximal in the yellow-orange region of the visible spectrum, this suggested that HAB was bound to specific proteins with strong

target-induced bathochromic fluorogenesis and FTOs (Fig. 4e and f). This labeling displayed a neat pattern of punctuated areas that first appeared by 32 hpf in the ventral tail of the embryo (Fig. 5a and e). The number and intensity of HAB fluorescent spots progressively increased at 48 hpf and 72 hpf (Fig. 5b, f and c, g) following the known deployment of macrophages and neutrophils during zebrafish development,<sup>4,5</sup> suggesting that these cell types could be targeted by HAB. The shape and size of the fluorescent spots within the caudal region of the specimens suggested labeling of some



subcellular compartment rather than whole cells.<sup>5</sup> It is noteworthy that the already autofluorescent pigment cells present in 72 hpf larvae showed a significant increase of fluorescence in the presence of **HAB** (Fig. 5c and d) suggesting that the probe also accumulated within these cells due to their high content of aromatic pigments (*i.e.*, pteridine and guanine derivatives).<sup>33,34</sup>

### HAB labeling is reversible

**HAB** labeling was found to be fairly photostable under the conditions used so far, with *ca.* 50% fluorescence lost after 30 min of continuous illumination at 488 nm. However, since the embryos and larvae were systematically washed and mounted in **HAB**-free agarose for live imaging, the diffusion of **HAB** out of its binding sites might be responsible for the loss of labeling overtime. To discriminate between free diffusion and photobleaching as the two possible causes of signal loss, we performed time-lapse imaging experiments in which either of these two phenomena was kept to a minimum. To test the free diffusion hypothesis, 72 hpf zebrafish larvae were treated with 10  $\mu\text{M}$  **HAB** for 1 h, washed and mounted in tracer-free mounting medium, and then imaged over time with short exposure-acquisition pulses every 10 min. Under these conditions of lower illumination hence limited photobleaching, the detection of **HAB**-labeled structures was no longer possible after *ca.* 1 h, with again *ca.* 50% of fluorescence lost after 30 min

exposure (see Fig. S3 in the ESI†). To test the photobleaching hypothesis, we treated the 72 hpf larvae with 10  $\mu\text{M}$  **HAB** for 1 h and mounted them in agarose and tricaine containing 10  $\mu\text{M}$  **HAB**. We then imaged the zebrafish larva embedded in **HAB** 10  $\mu\text{M}$  over time under continuous illumination by the 488 nm laser. Under these conditions of maximum photobleaching and abolished free diffusion, **HAB** labeling proved highly photostable, as it could be detected for up to 15 h of time-lapse imaging (see Video S4 in the ESI†). This observation indicates that **HAB** bound *in vivo* continually exchanges with free non-fluorescent **HAB**, at a rate faster than the photobleaching of the bound **HAB** during continuous 488 nm laser illumination. These conditions of constant equilibrium by continuous contact, made possible by the absence of **HAB** fluorescence in aqueous media, constitute optimal settings for **HAB** labeling on the zebrafish model and are particularly suitable for long-term experiments.

### HAB labels neutrophil granules in live zebrafish larvae

To identify the cell type(s) labeled by **HAB**, which according to their localization and developmental timing of detection could be the first leukocytes of the zebrafish embryo and larva (macrophages and/or neutrophils), we stained zebrafish transgenic 72 hpf larvae harbouring fluorescent macrophages or neutrophils<sup>35–37</sup> with **HAB**. Upon treatment with 10  $\mu\text{M}$  **HAB** of *Tg(mfap4:mCherry-F)* larvae possessing red-fluorescent




Fig. 5 **HAB** labels specific cells in live zebrafish from 32 hpf. Confocal fluorescence imaging of **HAB** labeling (10  $\mu\text{M}$ ) in live wild-type zebrafish embryos (32 and 48 hpf) and swimming larvae (72 hpf) following excitation at 488 nm and detection in the 550–650 nm range. The yellow-orange color is indicative of the fluorescence seen with the naked eye. Maximum intensity Z-projection images (2  $\mu\text{m}$  serial optical sections) are shown. Arrows point to the **HAB** label; asterisks mark pigment cells. A, artery; N, notochord; V, vein.



macrophages expressing mCherry, we found that the probe did not co-localize with the red-fluorescent macrophages (Fig. 6a–d). Due to the wide emission range of the mCherry protein (560–760 nm), which overlapped with that of the yellow-orange emitting **HAB**, mCherry was imaged following excitation at 552 nm and collecting only the “far red” portion of its fluorescence emission (660–750 nm), and **HAB** was imaged following excitation at 448 nm and collecting the 550–650 nm range of its emission spectrum. Upon treatment with 10  $\mu$ M **HAB** of Tg(*mpx*:GAL4/UAS-E1b:nsfB-mCherry) larvae harbouring neutrophils expressing mCherry and using the same **HAB**/mCherry acquisition parameters as above, we could show that **HAB** perfectly colocalized with all neutrophils of the imaged ventral tail region, labeling a specific compartment within them (Fig. 6e–h). Using GFP-labeled neutrophils (Tg(*mpx*:GFP) strain), and sequentially detecting GFP emission in the 500–520 nm range and **HAB** using the “red” portion of its emission spectrum (>600 nm) by exciting both fluorophores by the 448 nm laser (Fig. 6i–l) we confirmed that **HAB** targeted a neutrophil-specific compartment. Not only did **HAB** stain all neutrophils of the ventral tail region of 72 hpf larvae, where they are known to be particularly abundant,<sup>2,4,37</sup> but **HAB**-labeled neutrophils could also be found around the eye, ear and in the yolk sac of 72 hpf larvae (data not shown), indicating that **HAB** labels the entire neutrophil population *in vivo*. Collectively, these observations demonstrated that zebrafish neutrophils are the cell type selectively targeted by **HAB**, which specifically labels a compartment within these cells. To identify the compartment targeted by **HAB** within neutrophils, we performed high-resolution confocal imaging of **HAB**-labeled cells in 72 hpf larvae harbouring red neutrophils, combining the fluorescence detection of **HAB** and mCherry with DIC microscopy. **HAB** was found to co-localize with neutrophil granules, which are easily recognizable in transmitted light/DIC imaging<sup>5,38</sup> for they are refractile and constantly moving in the cytoplasm (Fig. 6m–p). This colocalization was unambiguously demonstrated by the perfect overlap of fluorescence **HAB** signals and DIC images during time-lapse acquisitions of live patrolling neutrophils (see high-resolution Videos S5 and S6 in the ESI†). Similar to their mammalian counterpart, the granules of zebrafish neutrophils contain myeloperoxidase.<sup>2,38,39</sup> The diazo dye Sudan Black B (SB) is a classical lipid stain that specifically labels the myeloperoxidase-positive granules of zebrafish neutrophils,<sup>5,40</sup> as also observed in human neutrophils.<sup>41,42</sup> The first SB-stained granules are detected by 32–35 hpf in zebrafish embryos, within the first, still immature embryonic neutrophils; this staining then increases in number and intensity, revealing the deployment of neutrophils during zebrafish development.<sup>5</sup> To check that **HAB** was targeting the same granule population as SB in neutrophils, we tried to combine the two dyes. We first tested if the **HAB** label was compatible with the fixation protocol classically used to fix zebrafish embryos and larvae, but failed to detect **HAB** labeling in the larva post-fixation for two hours at room temperature with either 1 or 4% formaldehyde, or when performing **HAB** labeling before the fixation. This could be due to the loss of

**HAB** pharmacology in fixed samples, or to the reaction of **HAB** with formaldehyde, leading to fluorophore destruction: even though **HAB** is both a very weak organic base (predicted  $pK_a$  value of 3.97 for its amino tautomers, see Fig. S7 in the ESI†) and a weak nucleophile, possessing the electronic features of a vinyllogous amide, this possibility cannot be ruled out in the absence of a dedicated study. In any case, it was not possible to combine the SB staining with the **HAB** labeling.

### **HAB** reveals the behavior of neutrophil granules during phagocytosis in live zebrafish larvae


To circumvent this technical limitation, we sought further evidence for the identity of neutrophil granules as the targets of **HAB**. One of the most important functions of neutrophils is to eliminate invading microorganisms. Neutrophils are highly phagocytic cells, able to engulf and kill microbes with the arsenal of microbicidal compounds stored in their granules. Once they have engulfed microbes, neutrophils release the granule content (*e.g.*, myeloperoxidase-produced hypochlorous acid and proteases) into the phagosome. We have shown that *in vivo*, zebrafish neutrophils degranulate into the phagosome following microbe phagocytosis and that the myeloperoxidase activity initially contained in the granules often relocates to the phagosome, while the SB staining correlatively disappears.<sup>43</sup> These steps have been advantageously reproduced with opsonized zymosan particles in cultured mammalian neutrophils, to show that neutrophil granules are recruited to the nascent phagosome in which they deliver their content by exocytosis.<sup>8,44</sup> To determine whether **HAB** would allow the visualization of neutrophil granule dynamics during phagocytosis *in vivo*, we vitally stained a zebrafish larva with **HAB**, then subcutaneously injected red-fluorescent Cy5-zymosan, and immediately monitored the interaction between **HAB**-labeled neutrophil granules and zymosan particles by high resolution confocal imaging (Fig. 7). We found that upon zymosan phagocytosis, **HAB**-labeled granules are massively recruited to the particle-containing phagosomes (Fig. 7a, b, d and related Video S8† in ESI), similar to the myeloperoxidase containing SB-labeled granules which we found relocated around the zymosan-containing phagosome in the fixed larva (Fig. 7c). These observations strongly suggest that the myeloperoxidase-containing granules are the targets of **HAB** *in vivo*. They also represent, to our knowledge, the first documentation of the dynamics of neutrophil degranulation upon phagocytosis in an entire live organism.

### **HAB** does not target neutrophil myeloperoxidase, and the staining of neutrophil granules by **HAB** is not a general feature of chalcones

To tentatively identify the specific protein target of **HAB** in the neutrophil granules, we performed **HAB** labeling in myeloperoxidase knock-out zebrafish larvae (“spotless” mutant strain)<sup>45</sup> under equilibrium conditions. While mutant larvae showed the expected absence of SB staining, they nevertheless still exhibited a fluorescent labeling with **HAB** qualitatively and quantitatively indistinguishable from wild-type larvae (Fig. 8a–d). This result shows that the myeloperoxidase abundant in neutrophil








**Fig. 6** HAB labels zebrafish neutrophil granules. (a–l) Confocal fluorescence imaging of HAB (10  $\mu$ M) in live transgenic 72 hpf zebrafish larvae following excitation at 448 nm under equilibrium conditions. Detection parameters were as follows: for HAB/mCherry:  $\lambda_{\text{ex}}$  448 nm,  $\lambda_{\text{em}}$  550–650 nm, mCherry:  $\lambda_{\text{ex}}$  552 nm,  $\lambda_{\text{em}}$  660–750 nm using sequential modes of acquisition. For GFP/HAB: GFP  $\lambda_{\text{ex}}$  448 nm,  $\lambda_{\text{em}}$  500–520 nm, HAB:  $\lambda_{\text{ex}}$  448 nm,  $\lambda_{\text{em}}$  550–650 nm using sequential modes of acquisition. Maximum intensity Z-projection images (2  $\mu$ m serial optical sections) are shown. (m–p) High-resolution DIC and confocal fluorescence imaging of HAB (10  $\mu$ M) in live 72 hpf zebrafish larvae harbouring red neutrophils. Arrows point to HAB-labeled granules according to the DIC images in neutrophils. A single 0.4  $\mu$ m optical section is shown. Boxes in (c), (g) and (k) indicate the regions magnified in the insets (d), (h) and (l) respectively. Abbreviations used: A (aorta); N (notochord); V (vein); asterisk = nucleus. See ESI for Videos S5 and S6† related to (m–p).

granules is not the biochemical target of **HAB**. We also tested a selection of biologically active chalcones as possible **HAB** competitors, based on their known or putative action on neutrophils such as inhibition of myeloperoxidase activity or repressing effects on pro-inflammatory mediators such as NF- $\kappa$ B, TNF- $\alpha$ , COX-2 and various interleukins.<sup>46–48</sup> The natural chalcones flavokawain **16** and cardamonin **17** are potent anti-inflammatory, proapoptotic and antitumour agents in mouse models, due to their ability to block NF- $\kappa$ B signaling.<sup>31,49–51</sup>

Synthetic chalcone **18** is an inhibitor of chemokine CXCL12 that blocks its binding to several chemokine receptors, preventing eosinophil infiltration in an asthma mouse model.<sup>52</sup> 3-Nitrochalcone **15** possesses pronounced antinociceptive properties in mice that are anti-inflammatory in origin.<sup>53</sup> Last, 4-methylchalcone **19** was selected due to its homology with mere (unsubstituted) chalcone, reported to exert anti-myeloperoxidase and anti-migratory effects on zebrafish neutrophils.<sup>46</sup> Larvae were first incubated with the competitors








**Fig. 7** HAB reveals the dynamics of neutrophil granules upon phagocytosis of zymosan particles in live zebrafish. (a and b) Confocal live imaging of HAB-labeled neutrophil granules upon phagocytosis of subcutaneously injected zymosan in a live 72 hpf zebrafish larva under diffusion conditions. HAB is recruited to the forming phagosomes (arrows). Inset: HAB labeling of a resting neutrophil. (c) Sudan Black (SB) staining of myeloperoxidase-containing neutrophil granules showing granule recruitment to the phagosome upon zymosan phagocytosis in fixed zebrafish larvae. Inset: SB staining of a resting neutrophil; a single 1 μm optical section is shown. (d) Frames extracted from an *in vivo* time-lapse confocal imaging sequence (time step = 1 min). Arrows point to HAB-labeled neutrophil granules that are recruited to the nascent zymosan containing phagosome. Three neutrophils (pointed with number 1 to 3) were tracked during the time lapse sequence. Maximum intensity Z-projection (1 μm serial optical sections). See ESI for Video S8† related to (d).

alone at 100 μM for 1 h to assess their toxicity, as well as possible basal fluorescence in the zebrafish. Under these conditions, all specimens remained alive with no apparent toxicity from the chalcones. Moreover, using the same detection settings as for HAB at 10 μM ( $\lambda_{\text{ex}}$  488 nm,  $\lambda_{\text{em}}$  550–650 nm), none of the competitors showed fluorescence and their labeling was undistinguishable from that of the negative control DMSO (data not shown), except for chalcone 18 (see

below and Fig. S9 in the ESI†). When these various potential competitors were co-incubated at 100 μM with HAB at 10 μM under the same conditions, we could observe no extinction or diminution of HAB fluorescence *in vivo* with any of these competitors relative to the control (Fig. 8e–j). Moreover, fluorimetric association experiments in TRIS buffer or DMF (where HAB shows the same type of yellow-orange fluorescence as in neutrophil granules, see Fig. 4d) demonstrated that none of







**Fig. 8** HAB does not target zebrafish neutrophil myeloperoxidase, and its binding to neutrophil granules is not a general feature of chalcones. (a and c) Merged confocal fluorescence and bright-field imaging of **HAB** (10  $\mu\text{M}$ ) in live wild-type (a) or “Spotless” (NL 144\_01 mutant: null *mpx* allele) (c) 72 hpf zebrafish larvae following excitation at 488 nm and detection in the 550–650 nm range under diffusion conditions. (b and d) SB staining of myeloperoxidase-containing neutrophil granules in bright-field imaging. (e–j) Merged confocal fluorescence and bright-field imaging of **HAB** (10  $\mu\text{M}$ ) in live wild-type 72 hpf zebrafish larvae co-treated with chalcones **15**, **16** (flavokawain A), **17** (cardamomin), **18** or **19** (100  $\mu\text{M}$ ) following excitation at 488 nm and detection in the 550–650 nm range under diffusion conditions. The yellow-orange color is indicative of the fluorescence seen with the naked eye. Single 2  $\mu\text{m}$  optical sections are shown. Abbreviations used: A (aorta); N (notochord); UGO (urogenital opening); V (vein).

these chalcones, when incubated in the presence of **HAB** at the same 10 : 1 stoichiometry, induced any significant qualitative or quantitative change in **HAB** fluorescence. The only exception was chalcone **18** which caused strong emission quenching in both media (data not shown), a feature not observed in zebrafish larvae *in vivo* (Fig. 8g). The binding of **HAB** to neutrophil granules thus appears to be the result of the probe's precise physicochemical signature, rather than a general feature of chalcones.

During the course of this competition study, we discovered that 4-hydroxy-3-methoxy-4'-chlorochalcone (Cpd. **18**) at 100  $\mu\text{M}$  was responsible for unusual fluorescence in the presence of

**HAB** (Fig. 8g), and deserved further investigation. When incubated alone at the same concentration on 72 hpf larvae and excited at 488 nm, chalcone **18** exhibited a green-yellow fluorescence that illuminated the anatomy of the specimens. Indeed, confocal imaging showed that the fluorescence of **18** delineated the trunk neuromasts, somite muscle fibers and boundaries, blood vessels, notochord, spinal cord, spinal canal and caudal hematopoietic tissue (Fig. S9 in the ESI†). Detailed examination revealed no detectable intracellular staining, but interstitial histological labeling. This behavior is reminiscent of that of BODIPY-ceramide, a fluorescent dye previously used at similarly high concentration as a histological counterstain for



the confocal imaging of live zebrafish embryos.<sup>54,55</sup> The fact that chalcone **18** was not cytopermeable even at high concentration further validates the global design of **HAB**, a benzochalcone congener, as a histo- and cytopermeable tracer for *in vivo* studies. Interestingly, chalcone **18** was recently evaluated in the zebrafish model as an inhibitor of the chemokine CXCL12a, for its activity against the collective migration of cells of the posterior lateral line primordium. At 10  $\mu\text{M}$ , **18** showed moderate biological effects and was not fluorescently detected by GFP filters.<sup>56</sup> The complete study of chalcone **18** regarding the fluorescence detection threshold, photostability, phenotypic effects and long-term toxicity is currently underway, in order to validate this compound as a novel anatomical interstitial live stain in the zebrafish model.

### HAB labels granules in live human primary neutrophils

In order to validate **HAB** as a specific vital stain of neutrophil granules not only in fish but also in mammals, and to assess its relevance for human studies, we attempted the **HAB** labeling of live primary human neutrophils freshly isolated from total blood. Human neutrophils exist in two morphologically and phenotypically distinct forms depending on their state of activation. Whereas non-activated neutrophils consist of round-shaped non-adhering circulating cells, activated neutrophils are polyhedral cells expressing a number of cytoadhesins and adhering to endothelium walls, glass or plastic surfaces.<sup>57,58</sup> When stained with 10  $\mu\text{M}$  **HAB**, non-activated neutrophils exhibited intense but diffuse fluorescent labeling, presumably due to the difficulty of resolving subcellular structures when imaging non-adherent cells (Fig. 9a–c). An equally intense labeling of cells at the level of subcellular granular structures was detected under the same conditions in activated neutrophils, consistent with the morphology and distribution of human neutrophil granules,<sup>59,60</sup> in addition to a strong perinuclear staining possibly corresponding to the nuclear membrane (Fig. 9d–f and S10 in the ESI†). To address the human blood cell selectivity issue, we assessed **HAB** labeling on other freshly isolated cell populations from whole human blood (peripheral blood mononuclear cells, PBMC) under the same conditions as those used to image purified neutrophils. **HAB** was found to exhibit an impressive selectivity for neutrophils over lymphocytes, monocytes, erythrocytes and thrombocytes (platelets), which were all weakly to faintly labeled (Fig. 9g–i). This selectivity seems to be the result of the accumulation of **HAB** in neutrophil granules, consistent with the complete cell and organelle specificity observed in the zebrafish model *in vivo*. Although these results deserve further investigation regarding the subset of granules labeled in human neutrophils,<sup>59</sup> they constitute a strong presumption that the specific labeling of neutrophil granules by **HAB** in the zebrafish model is also relevant to mammalian systems.


## Discussion

A novel 3-aminobenzochalcone, **HAB**, was rationally designed, synthesized and validated as a histopermeable and

fluorogenic vital stain for *in vivo* biological studies. Physically, **HAB** has elevated Stokes shifts, the highest fluorescence quantum yield described to date in this series, elevated signal-to-noise ratios upon protein binding, and unprecedented photostability. This also chemically very stable tracer possesses the minimal architecture to be strongly fluorescent, and stains neutrophils in zebrafish embryos and larvae with extraordinary specificity, with no labeling of other, even related, cell types (*e.g.*, macrophages). Subcellularly, **HAB** proved to be specific for zebrafish neutrophil granules, with no staining of other organelles or compartments. This behavior was rationalized as target-induced bathochromic fluorogenesis based on various chemical and biochemical model systems. Neutrophil labeling was independent of the state of cell activation, since **HAB** stained the granules of both resting and phagocytically active neutrophils with equal intensity and specificity. **HAB** labeling in the zebrafish followed the deployment of neutrophils from 32 hpf embryos to 72 hpf swimming larvae and was even visualised in neutrophil granules in 6 day-old larvae with similar sensitivity despite the increase in tissue density and thickness (see Fig. S11 in the ESI†). Due to its absence of toxicity up to 48 h incubation and outstanding photostability, **HAB** is ideal for the long-term, high temporal resolution live imaging of developing zebrafish, with the potential of dynamic monitoring of the neutrophil granules in virtually any physiological or physiopathological context. To our knowledge, no other related tracer is endowed with such precious characteristics. Last, **HAB** intensely labeled freshly purified neutrophils from human blood at the level of granular structures consistent with neutrophil granules. Fluorescent dyes for neutrophil granules are limited, including quinacrine (QA),<sup>8</sup> LysoTrackerRed® (LTR),<sup>9</sup> dihydrorhodamine (DHR) 123,<sup>9</sup> and rhodamine-thiolactones (RTLs),<sup>61</sup> which are non-specific by essence. QA and LTR as weak bases constitute general acidotropic stains, sequestered in their protonated form in various low pH organelles and vesicles (*e.g.*, lysosomes,<sup>62–64</sup> apoptotic vesicles,<sup>65</sup> mast cell granules<sup>66,67</sup>), to which mammalian basophil and neutrophil secreted granules also belong.<sup>68,69</sup> DHR 123 and RTLs are part of ROS-activated profluorophores used to detect hydrogen peroxide/peroxynitrite and hypochlorous acid, respectively, in activated neutrophils as well as in various other cell systems and organelles.<sup>61,70–72</sup> A comparative analysis of the various existing tracers of neutrophil granules is provided in Table 1. In marked contrast, the unique staining of live zebrafish neutrophil granules by **HAB** over other cell types and acidic compartments in the whole organism, together with **HAB** very weak basicity (about  $10^5$ -fold lower than that of acidotropic amines<sup>63</sup> with a predicted  $pK_a$  value of 3.97 for the amino tautomers, see Fig. S7 in the ESI†) supports a specific target-induced labeling of neutrophil granules by **HAB**. Although we showed that the myeloperoxidase present in the granules is not involved in their specific staining by **HAB**, these granules also contain abundant neutral serine proteases (*e.g.*, elastase, proteinase 3, and cathepsin G),<sup>59</sup> which constitute putative biochemical targets for **HAB** based on their reactivity







**Fig. 9** HAB selectively labels live human primary neutrophils over other blood cell types. (a–c and d–f) confocal fluorescence and DIC imaging of HAB (10  $\mu\text{M}$ ) in live human neutrophils following excitation at 448 nm and detection in the 550–650 nm range. Single 0.4  $\mu\text{m}$  optical sections are shown. (a–c) show resting, non-activated, non-adherent neutrophils. (d–f) show activated, adherent neutrophils: note HAB staining of neutrophils granules (g–i): confocal fluorescence and DIC imaging of HAB (10  $\mu\text{M}$ ) in live human lymphocytes (lc), erythrocytes (ec), monocytes (mc) and thrombocytes (tc) using the same settings as in (a–c) and (d–f). Single 0.4  $\mu\text{m}$  optical sections are shown. The yellow-orange color is indicative of the fluorescence seen with the naked eye. Asterisk = nucleus.

towards reversible electrophilic inhibitors.<sup>73,74</sup> In this context, **HAB** has an immediate surrogate for proteomic interrogation in the form of a photoalkylative azido analogue (Fig. 1) easily accessible through Sandmeyer-type modification of the aromatic amino group.<sup>22</sup> The covalent photolabeling of live zebrafish larvae or isolated human neutrophils with a fluorogenic 3-azido-4'-hydroxybenzoaldehyde, FACS purification of labeled cells followed by Western Blot identification of the covalently stained molecular target(s) of **HAB**, therefore seems within reach. Overall, due to its optimal photophysical

and physicochemical properties and unprecedented biological specificity, **HAB** constitutes a valuable small-molecule addition to the fluorescent proteins toolbox used in the zebrafish model, which it functionally and spectrally complements, and appears suitable for functional studies in live mammalian neutrophils. **HAB** therefore holds great promise as a vital stain to monitor the dynamics and behaviour of neutrophil granules in various aspects of the neutrophil function in the context of a live organism, with potential relevance to human physiology and physiopathology.



Table 1 Functional comparison of HAB with existing tracers of neutrophil granules<sup>a</sup>

Tracer	Specificity for neutrophil granules	Histopermeability for live animal imaging	Photostability	Fluorogenesis	Ref.
Quinacrine	No (acidotropic stain, DNA stain)	Yes	Yes	No	8, 65 and 75–77
LysoTrackers	No (acidotropic stains)	Yes	No	No	9, 65 and 77–79
Acridine orange	No (acidotropic stain, DNA/RNA stain)	Yes	Yes	No	65 and 80–83
Dihydrorhodamine 123	No (ROS/RNS-dependent - also labels mitochondria)	No ( <i>in vitro</i> only)	No	Yes (ROS-activated)	9 and 84–87
Rhodamine-thiolactones	No (ROS-dependent)	Yes	Yes	Yes (ROS-reactive)	61 and 88
Sudan Black B	Yes (lipids/MPO-dependent)	No (FA fixation <i>in vivo</i> )	NA (colorimetric stain)	NA (colorimetric stain)	5, 42 and 89
Luminol	No (ROS-dependent, MPO-amplified)	No ( <i>in vitro</i> only)	NA (chemiluminescent stain)	NA (chemiluminescent stain)	90
Tyramide-FITC/Cy3	Yes (MPO-reactive)	No (FA fixation <i>in vivo</i> )	No (FITC conjugate) Yes (Cy3 conjugate)	No	5 and 91
MUB40/RI-MUB40-Cy5	Yes (lactoferrin ligands)	No (peptides, FA fixation <i>in vitro</i> , <i>in vivo</i> )	Yes	No	60
NE680	Yes (elastase substrate)	No (peptide, MeOH fixation <i>ex vivo</i> , intranasal instillation in mouse)	Yes	Yes (enzyme-activated)	92
Elastase, cathepsin G, proteinases 3 and 4 substrates	Yes (enzyme substrates)	No (peptides, FA fixation <i>in vitro</i> )	Yes	Yes (enzyme-activated)	93
<b>HAB</b>	Yes (pH, ROS, MPO-independent fluorescence)	Yes (amphipathic small-molecule, log $D_{7.4}$ = 2.21)	Yes (>15 h under continuous 488 nm irradiation)	Yes (target protein-induced FTO)	Our study

<sup>a</sup> FA, formaldehyde; FITC, fluorescein isothiocyanate; FTO, fluorescence turn-on; MeOH, methanol; MPO, myeloperoxidase; NA, non-applicable; RNS, reactive nitrogen species; ROS, reactive oxygen species.

## Methods

### Compound synthesis, structural characterization and $pK_a$ prediction

Detailed synthetic procedures and analytical identification for compounds 2–8, 10–12 and 14, as well as  $pK_a$  prediction for HAB, can be found in the ESI.†

### Zebrafish

Transgenic and mutant stocks of zebrafish were raised and staged according to Westerfield.<sup>94</sup> AB wild-type fish and transgenic lines Tg(*mpx*:GFP)<sup>i114</sup>, Tg(*mpx*:GAL4.VP16)<sup>i22</sup>, Tg(*mfap4*:mCherry-F) and Tg(UAS-E1b:nfsB.mCherry)<sup>c264</sup> were used.<sup>35–37</sup> Embryos were reared at 28 °C or 24 °C according to the desired speed of development. All timings in the text refer to the developmental stage at the reference temperature of 28.5 °C.<sup>94</sup> Embryos and larvae were anesthetized with 200  $\mu\text{g mL}^{-1}$  tricaine (Sigma-Aldrich) during live *in vivo* imaging.

### HAB labeling of live zebrafish embryos and larvae

**Equilibrium protocol (Fig. 6, S4 and S11, Videos S5 and S6†).** 72 hpf or 6 dpf zebrafish larvae, either wild-type AB specimens or transgenic specimens, were placed in individual wells (24-well culture plates; 10 larvae per well), incubated with HAB (10

$\mu\text{M}$  in Volvic water from 10 mM stock solutions in DMSO) at room temperature for 1 h in the dark, anaesthetized in buffered tricaine (Sigma) containing HAB (10  $\mu\text{M}$ ) and then mounted in 35 mm glass-bottom dishes (Inagaki-Iwaki) in 1% low-melting-point agarose containing HAB (10  $\mu\text{M}$ ) to ensure equilibrium conditions. The immobilized larvae were then covered with 2 mL Volvic water containing tricaine and HAB (10  $\mu\text{M}$ ) as described previously.<sup>43</sup> Negative controls consisted of Volvic water containing 0.1% DMSO. For wild-type AB specimens as well as transgenic specimens, HAB was incubated for 1 h.

**Diffusion protocol (Fig. 5, 7 and S3, Video S8†).** Wild-type AB zebrafish embryos and swimming larvae (24 hpf to 72 hpf) were placed in individual wells (24-well culture plates; 10 larvae per well), incubated with HAB (10  $\mu\text{M}$  in Volvic water from 10 mM stock solutions in DMSO) at room temperature for 1 h in the dark, washed, anaesthetized in HAB-free buffered tricaine (Sigma) and then mounted in 35 mm glass-bottom dishes (Inagaki-Iwaki) in HAB-free 1% low-melting-point agarose. The immobilized larvae were then covered with 2 mL Volvic water containing tricaine as described previously.<sup>43</sup> Negative controls consisted of Volvic water containing 0.1% DMSO. Practically, homogenous aqueous solutions of HAB were obtained by adding the drop of stock DMSO solutions on the inner wall of a plastic tube containing Volvic water at room temperature (20–23 °C), and vortexing without interruption for 20 s.



### Sudan Black staining (Fig. 7 and 8)

Zebrafish larvae (72 hpf) were fixed with 4% methanol-free formaldehyde (Poly-sciences, Warrington, PA) in phosphate-buffered saline (PBS) for 2 hours at room temperature, rinsed in PBS, incubated in Sudan Black (SB; Sigma-Aldrich) for 20 minutes, washed extensively in 70% ethanol in water, and then progressively rehydrated in 0.1% Tween 20 in PBS as previously described.<sup>5</sup>

### Zyosan microinjection in zebrafish larvae (Fig. 7)

Zebrafish larvae (72 hpf) were anaesthetized by immersion in buffered tricaine immediately after the **HAB** labeling. They were injected with 1 nL of  $0.4 \times 10^8 \text{ mL}^{-1}$  zyosan-Cy5 particle suspension using pulled borosilicate glass microcapillary (GC100F-15 Harvard apparatus) pipettes under a stereomicroscope (Stemi 2000, Carl Zeiss, Germany) with a mechanical micromanipulator (M-152; Narishige), and a Picospritzer III pneumatic microinjector (Parker Hannifin) set at a pressure of 20 psi and an injection time of 20 ms (subcutaneous injections) as previously described.<sup>43</sup>

### Competition experiments (Fig. 8)

72 hpf wild-type AB zebrafish larvae were placed into individual wells as previously described and co-incubated for 1 h at room temperature with **HAB** (10  $\mu\text{M}$  from a 10 mM stock solution in DMSO) and each competitor (100  $\mu\text{M}$  from a 10 mM stock solution in DMSO) in Volvic water in the dark as previously described. Negative controls consisted of Volvic water containing 1.1% DMSO. In this case, specimens were rapidly rinsed, anaesthetized and mounted in **HAB**-free media for biological imaging. Practically, homogenous aqueous solutions of **HAB**  $\pm$  competitors were obtained by adding the drop of stock DMSO solutions on the inner wall of a plastic tube containing Volvic water at room temperature (20–23 °C), and vortexing without interruption for 20 s.

### HAB labeling of live human neutrophils (Fig. 9 and S10†)

Peripheral human blood was collected from healthy patients at the ICAReB service of the Pasteur Institute (authorization DC no. 2008-68). All donors gave written informed consent in accordance with the Declaration of Helsinki principles. Blood was collected from the antecubital vein into tubes containing sodium citrate (3.8% final) as the anticoagulant. Human polymorphonuclear neutrophils were purified as described previously.<sup>95</sup> Briefly, plasma was removed by centrifugation (450g, 15 min), and blood cells were resuspended in 0.9% NaCl solution supplemented with 0.72% Dextran. After red blood cell sedimentation, white blood cells were pelleted and further separated on a two layer Percoll (GE Healthcare) gradient (51–42%) by centrifugation (240 g, 20 min). Peripheral Blood Mononuclear Cells (PBMC) (top layer) were isolated from polymorphonuclear neutrophils (bottom layer). Red blood cells were removed from the latter fraction using CD235a (glycophorin) microbeads (Miltenyi Biotec). Purified polymorphonuclear neutrophils were resuspended in the

autologous plasma until experimental use. For **HAB** labeling, they were immediately put in RPMI 10 mM Hepes at  $2 \times 10^6$  cells per mL. 1 mL of neutrophil suspension was distributed in 35 mm glass-bottom dishes and incubated at room temperature for 20 min for neutrophil adhesion. The medium was then replaced by the **HAB** staining solution (at 1, 5 or 10  $\mu\text{M}$ ) in RPMI 10 mM Hepes; after 5–15 min at room temperature, **HAB**-labeled neutrophils were observed with a SP8 Leica confocal microscope, using a 63 $\times$  water immersion objective. The 10  $\mu\text{M}$  **HAB** concentration gave the best results.

### Live imaging, image processing and analysis

Confocal microscopy to detect **HAB** single labeling in wild-type zebrafish embryos and larvae was performed at 23–26 °C using a Leica SPE inverted microscope and a 16 $\times$  oil immersion objective (PL FLUOTAR 16 $\times$ /0.50 IMM). **HAB** was excited with a 488 nm laser and the fluorescence emission was collected within the 550–650 nm range unless otherwise indicated. A Leica SP8 confocal microscope with a 20 $\times$  oil immersion objective (HC PL APO CS2 20 $\times$ /0.75 IMM) was used to live image transgenic larvae for colocalization studies and wt larvae for competition studies. Regarding **HAB**/mCherry acquisition, the following settings were applied: **HAB** (excitation 448 nm; emission 550–650 nm) and mCherry (excitation 552 nm; emission 660–750 nm) using a sequential acquisition mode. For GFP/**HAB** acquisition the following settings were applied: GFP (excitation 448 nm; emission 500–520 nm) and **HAB** (excitation 448 nm; emission >600 nm). A 40 $\times$  water immersion objective (HC PL APO CS2 40 $\times$ /1.1 water) was also used with the SP8 LEICA confocal microscope, to document at high resolution **HAB** labeling in neutrophils. For **HAB**-zyosan acquisition, the following settings were applied: **HAB** (excitation 488 nm; emission 491–601 nm) and Cy5-zyosan (excitation 638 nm; emission 683–795 nm). A 63 $\times$  water immersion objective (HC PL APO CS2 63 $\times$ /1.2 water) was used to image **HAB** in live human neutrophils, following excitation at 448 nm and collecting the fluorescence emission in the 550–650 nm range. The 3D or 4D files generated by the confocal acquisitions were processed using the LAS-AF Leica software. Acquired Z-stacks (2  $\mu\text{m}$  serial optical sections for images taken using 16 $\times$  and 20 $\times$  objectives) were projected using maximum intensity projection and exported as AVI or TIFF files. Z stacks acquired with the 40 $\times$  or 63 $\times$  objectives (0.4  $\mu\text{m}$  to 1  $\mu\text{m}$  serial optical sections) were exported as the AVI file. Frames were captured from the AVI files and handled with PowerPoint software to mount figures.

### Author contributions

E. C.-G. designed, performed and analysed the **HAB**-zebrafish experiments and contributed to the writing of the manuscript. A. S. B. and S. D. S. O. performed **HAB** phenotypic screening. M. B. and I. C. B. performed the fluorescence spectroscopy experiments. B. S. M. provided human neutrophils and PBMC. K. L. performed the HRMS analysis. P. H. assisted with helpful discussion and participated in the writing of the manuscript. R. D. designed **HAB**, performed the synthesis and structural





analysis of all compounds, performed log  $D_{7.4}$  measurements, co-analysed all biological experiments, and wrote the manuscript.

## Conflicts of interest

The authors declare no competing financial interests.

## Abbreviations

AcOEt	Ethyl acetate
AcOH	Acetic acid
BF	Bright field
CC	Column chromatography
CHCl <sub>3</sub>	Chloroform
DHR	Dihydrorhodamine
DIC	Differential interference contrast
DMF	Dimethylformamide
DMSO	Dimethylsulfoxide
DPP	<i>N</i> -Dansyl- <i>N'</i> -phenylpiperazine
FACS	Fluorescence-activated cell sorting
<i>F</i>	Fluorescence quantum yield
HAB	4'-Hydroxy-3-aminobenzochalcone
HRMS	High-resolution mass spectra
ICG	Indocyanine green
LTR	LysoTrackerRed
MeCN	Acetonitrile
MPO	Myeloperoxidase
PBMC	Peripheral blood mononuclear cells
ROS	Reactive oxygen species;
RTL	Rhodamine-thiolactone
QA	Quinacrine
SB	Sudan Black

## Acknowledgements

The authors wish to acknowledge the following contributors: Dr L. Bianchi and Prof. G. Petrillo for the generous gift of a reference of compound **10**; Dr P. Leal for the gift of xanthoxyline; Prof. S. Renshaw and Prof. G. Lutfalla for providing the zebrafish transgenic Tg(*mpx*:GAL4.VP16)<sup>i22</sup> and Tg(*mfap4*:mCherryF) lines, respectively; Dr F. Niedergang for the gift of Cy5-zymosan; T. M. R. Gianeti and Dr A. Maciuk for their practical help regarding NIR fluorescence and HRMS analysis, respectively; A. Blin for taking pictures of UVA-irradiated cuvettes in Fig. 4; Dr N. Bizat for preliminary labelling experiments in *C. elegans*; V. Briolat, Y. Rolin and N. Aimar for fish husbandry, as well as L. Boucontet for helping with zebrafish embryo preparation; Dr M. Anderson for the preparation of isolated human neutrophils; Dr A. Cras for fruitful discussions regarding the biology of human blood cells. R. Duval gratefully acknowledges Prof. R. J. Nunes, Prof. B. Rossi-Bergmann and Prof. N. Leulliot for permitting certain experiments to be conducted in their laboratories. Grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq (401897/2010-9 to R. D.), the Institut Pasteur (GPF Microbes and Brain Myconeuro, S-PI14032-02G to E. C.-G.) and

the Fondation pour la Recherche Médicale (Equipe FRM DEQ20120323714 to P. H.) are acknowledged, as well as Dr J. Moreira for translating the CNPq scientific proposal into Portuguese.

## References

- 1 S. Masud, V. Torraca and A. H. Meijer, *Curr. Top. Dev. Biol.*, 2017, **124**, 277–329.
- 2 G. J. Lieschke, A. C. Oates, M. O. Crowhurst, A. C. Ward and J. E. Layton, *Blood*, 2001, **98**, 3087–3096.
- 3 D. Traver, P. Herbomel, E. E. Patton, R. D. Murphey, J. A. Yoder, G. W. Litman, A. Catic, C. T. Amemiya, L. I. Zon and N. S. Trede, *Adv. Immunol.*, 2003, **81**, 253–330.
- 4 P. Herbomel, B. Thisse and C. Thisse, *Development*, 1999, **126**, 3735–3745.
- 5 D. Le Guyader, M. J. Redd, E. Colucci-Guyon, E. Murayama, K. Kissa, V. Briolat, E. Mordelet, A. Zapata, H. Shinomiya and P. Herbomel, *Blood*, 2008, **111**, 132–141.
- 6 K. M. Henry, C. A. Loynes, M. K. B. Whyte and S. A. Renshaw, *J. Leukocyte Biol.*, 2013, **94**, 633–642.
- 7 E. A. Harvie and A. Huttenlocher, *J. Leukocyte Biol.*, 2015, **98**, 523–537.
- 8 E. Suzuki, H. Kobayashi, Y. Kodama, T. Masujima and S. Terakawa, *Cell Motil. Cytoskeleton*, 1997, **38**, 215–228.
- 9 C. F. Bassoe, N. Y. Li, K. Ragheb, G. Lawler, J. Sturgis and J. P. Robinson, *Cytometry B Clin Cytom.*, 2003, **51**, 21–29.
- 10 R. Duval and C. Duplais, *Nat. Prod. Rep.*, 2017, **34**, 161–193.
- 11 N. DiCesare and J. R. Lakowicz, *Tetrahedron Lett.*, 2002, **43**, 2615–2618.
- 12 J. Prabhu, K. Velmurugan and R. Nandhakumar, *Spectrochim. Acta, Part A*, 2015, **144**, 23–28.
- 13 C. G. Niu, A. L. Guan, G. M. Zeng, Y. G. Liu and Z. W. Li, *Anal. Chim. Acta*, 2006, **577**, 264–270.
- 14 S. C. Lee, N. Y. Kang, S. J. Park, S. W. Yun, Y. Chandran and Y. T. Chang, *Chem. Commun.*, 2012, **48**, 6681–6683.
- 15 M. Tomasch, J. S. Schwed, L. Weizel and H. Stark, *Front. Syst. Neurosci.*, 2012, **6**, 14.
- 16 B. Zhou, P. Jiang, J. Lu and C. Xing, *Arch. Pharm.*, 2016, **349**, 539–552.
- 17 T. Fuchigami, Y. Yamashita, M. Haratake, M. Ono, S. Yoshida and M. Nakayama, *Bioorg. Med. Chem.*, 2014, **22**, 2622–2628.
- 18 H. G. O. Alvim, E. L. Fagg, A. L. de Oliveira, H. C. B. de Oliveira, S. M. Freitas, M. A. E. Xavier, T. A. Soares, A. F. Gomes, F. C. Gozzo, W. A. Silva and B. A. D. Neto, *Org. Biomol. Chem.*, 2013, **11**, 4764–4777.
- 19 A. Bessette, T. Auvray, D. Desilets and G. S. Hanan, *Dalton Trans.*, 2016, **45**, 7589–7604.
- 20 P. Alexander and H. Moronson, *Nature*, 1962, **194**, 2.
- 21 D. Kulms and T. Schwarz, *Skin Pharmacol. Appl. Skin Physiol.*, 2002, **15**, 342–347.
- 22 S. J. Lord, H. L. Lee, R. Samuel, R. Weber, N. Liu, N. R. Conley, M. A. Thompson, R. J. Twieg and W. E. Moerner, *J. Phys. Chem. B*, 2010, **114**, 14157–14167.
- 23 S. D. Barker, K. Wilson and R. K. Norris, *Aust. J. Chem.*, 1995, **48**, 1969–1979.



- 24 P. G. E. Alcorn and P. R. Wells, *Aust. J. Chem.*, 1965, **18**, 1377–1389.
- 25 V. Balasubramanian, *Chem. Rev.*, 1966, **66**, 567–641.
- 26 D. Skalamera, L. P. Cao, L. Isaacs, R. Glaser and K. Mlinaric-Majerski, *Tetrahedron*, 2016, **72**, 1541–1546.
- 27 A. Niemann, J. Baltés and H. P. Elsasser, *J. Histochem. Cytochem.*, 2001, **49**, 177–185.
- 28 X. J. Yang, C. M. Shi, R. Tong, W. P. Qian, H. E. Zhau, R. X. Wang, G. D. Zhu, J. J. Cheng, V. W. Yang, T. M. Cheng, M. Henary, L. Strekowski and L. W. K. Chung, *Clin. Cancer Res.*, 2010, **16**, 2833–2844.
- 29 R. A. Duval, R. L. Allmon and J. R. Lever, *J. Med. Chem.*, 2007, **50**, 2144–2156.
- 30 P. Boeck, C. A. B. Falcao, P. C. Leal, R. A. Yunes, V. Cechinel, E. C. Torres-Santos and B. Rossi-Bergmann, *Bioorg. Med. Chem.*, 2006, **14**, 1538–1545.
- 31 X. L. Zi and A. R. Simoneau, *Cancer Res.*, 2005, **65**, 3479–3486.
- 32 M. J. Waring, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 2844–2851.
- 33 I. Ziegler, T. McDonald, C. Hesslinger, I. Pelletier and P. Boyle, *J. Biol. Chem.*, 2000, **275**, 18926–18932.
- 34 C. W. Higdon, R. D. Mitra and S. L. Johnson, *PLoS One*, 2013, **8**, e67801.
- 35 Q. T. Phan, T. Sipka, C. Gonzalez, J. P. Levraud, G. Lutfalla and N. C. Mai, *PLoS Pathog.*, 2018, **14**, e1007157.
- 36 F. Ellett, L. Pase, J. W. Hayman, A. Andrianopoulos and G. J. Lieschke, *Blood*, 2011, **117**, E49–E56.
- 37 S. A. Renshaw, C. A. Loynes, D. M. I. Trushell, S. Elworthy, P. W. Ingham and M. K. B. Whyte, *Blood*, 2006, **108**, 3976–3978.
- 38 M. O. Crowhurst, J. E. Layton and G. J. Lieschke, *Int. J. Dev. Biol.*, 2002, **46**, 483–492.
- 39 C. T. Pham, *Nat. Rev. Immunol.*, 2006, **6**, 541–550.
- 40 K. Wang, X. Fang, N. Ma, Q. Lin, Z. Huang, W. Liu, M. Xu, X. Chen, W. Zhang and Y. Zhang, *Fish Shellfish Immunol.*, 2015, **44**, 109–116.
- 41 B. J. Bain, *Am. J. Hematol.*, 2010, **85**, 707.
- 42 W. van den Ancker, T. M. Westers, D. C. de Leeuw, Y. F. van der Veecken, A. Loonen, E. van Beckhoven, G. J. Ossenkoppele and A. A. van de Loosdrecht, *Cytometry, Part B*, 2013, **84**, 114–118.
- 43 E. Colucci-Guyon, J. Y. Tinevez, S. A. Renshaw and P. Herbomel, *J. Cell Sci.*, 2011, **124**, 3053–3059.
- 44 E. K. Macrae and K. B. Pryzwansky, *Carlsberg Res. Commun.*, 1984, **49**, 315–322.
- 45 P. M. Elks, M. van der Vaart, V. van Hensbergen, E. Schutz, M. J. Redd, E. Murayama, H. P. Spaink and A. H. Meijer, *PLoS One*, 2014, **9**, e100928.
- 46 Y. H. Chen, W. H. Wang, Y. H. Wang, Z. Y. Lin, C. C. Wen and C. Y. Chern, *Molecules*, 2013, **18**, 2052–2060.
- 47 B. P. Bandgar, S. A. Patil, R. N. Gacche, B. L. Korbad, B. S. Hote, S. N. Kinkar and S. S. Jalde, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 730–733.
- 48 J. Z. Wu, J. L. Li, Y. P. Cai, Y. Pan, F. Q. Ye, Y. L. Zhang, Y. J. Zhao, S. L. Yang, X. K. Li and G. Liang, *J. Med. Chem.*, 2011, **54**, 8110–8123.
- 49 D. J. Kwon, S. M. Ju, G. S. Youn, S. Y. Choi and J. Park, *Food Chem. Toxicol.*, 2013, **58**, 479–486.
- 50 N. Wu, J. Liu, X. Z. Zhao, Z. Y. Yan, B. Jiang, L. J. Wang, S. S. Cao, D. Y. Shi and X. K. Lin, *Tumor Biol.*, 2015, **36**, 9667–9676.
- 51 S. Hatzieremia, A. I. Gray, V. A. Ferro, A. Paul and R. Plevin, *Br. J. Pharmacol.*, 2006, **149**, 188–198.
- 52 M. Hachet-Haas, K. Balabanian, F. Rohmer, F. Pons, C. Franchet, S. Lecat, K. Y. C. Chow, R. Dagher, P. Gizzi, B. Didier, B. Lagane, E. Kellenberger, D. Bonnet, F. Baleux, J. Haiech, M. Parmentier, N. Frossard, F. Arenzana-Seisdedos, M. Hibert and J. L. Galzi, *J. Biol. Chem.*, 2008, **283**, 23189–23199.
- 53 F. de Campos-Buzzi, J. P. de Campos, P. P. Tonini, R. Correa, R. A. Yunes, P. Boeck and V. Cechinel-Filho, *Arch. Pharm.*, 2006, **339**, 361–365.
- 54 M. S. Cooper, L. A. D'Amico and C. A. Henry, *Methods Cell Biol.*, 1999, **59**, 179–204.
- 55 E. Murayama, M. Sarris, M. Redd, D. Le Guyader, C. Vivier, W. Horsley, N. Trede and P. Herbomel, *Nat. Commun.*, 2015, **6**, 1–14.
- 56 D. Dalle Nogare, K. Somers, S. Rao, M. Matsuda, M. Reichman-Fried, E. Raz and A. B. Chitnis, *Development*, 2014, **141**, 3188–3196.
- 57 N. Yakuwa, T. Inoue, T. Watanabe, K. Takahashi and F. Sendo, *Microbiol. Immunol.*, 1989, **33**, 843–852.
- 58 K. Ley, H. M. Hoffman, P. Kubes, M. A. Cassatella, A. Zychlinsky, C. C. Hedrick and S. D. Catz, *Sci Immunol.*, 2018, **3**, eaat4579.
- 59 J. L. Eyles, A. W. Roberts, D. Metcalf and I. P. Wicks, *Nat. Clin. Pract. Rheumatol.*, 2006, **2**, 500–510.
- 60 M. C. Anderson, T. Chaze, Y. M. Coic, L. Injarabian, F. Jonsson, N. Lombion, D. Selimoglu-Buet, J. Souphron, C. Ridley, P. Vonaesch, B. Baron, E. T. Arena, J. Y. Tinevez, G. Nigro, K. Nothelfer, E. Solary, V. Lapierre, T. Lazure, M. Matondo, D. Thornton, P. J. Sansonetti, F. Baleux and B. S. Marteyn, *Cell Chem. Biol.*, 2018, **25**, 483–493.
- 61 X. Chen, K. A. Lee, E. M. Ha, K. M. Lee, Y. Y. Seo, H. K. Choi, H. N. Kim, M. J. Kim, C. S. Cho, S. Y. Lee, W. J. Lee and J. Yoon, *Chem. Commun.*, 2011, **47**, 4373–4375.
- 62 D. D. Li, N. Ropert, A. Koulakoff, C. Giaume and M. Oheim, *J. Neurosci.*, 2008, **28**, 7648–7658.
- 63 B. Lemieux, M. D. Percival and J. P. Falgueyret, *Anal. Biochem.*, 2004, **327**, 247–251.
- 64 T. Sasaki, S. S. Lian, J. Qi, P. E. Bayliss, C. E. Carr, J. L. Johnson, S. Guha, P. Kobler, S. D. Catz, M. Gill, K. L. Jia, D. J. Klionsky and S. Kishi, *PLoS Genet.*, 2014, **10**, e1004409.
- 65 A. Pierzynska-Mach, P. A. Janowski and J. W. Dobrucki, *Cytometry, Part A*, 2014, **85**, 729–737.
- 66 M. Wu, T. Baumgart, S. Hammond, D. Holowka and B. Baird, *J. Cell Sci.*, 2007, **120**, 3147–3154.
- 67 H. Y. Chen, D. M. Chiang, Z. J. Lin, C. C. Hsieh, G. C. Yin, I. C. Weng, P. Guttermann, S. Werner, K. Henzler, G. Schneider, L. J. Lai and F. T. Liu, *Sci. Rep.*, 2016, **6**, 34879.
- 68 A. W. Segal, *Annu. Rev. Immunol.*, 2005, **23**, 197–223.



- 69 M. A. Kolber and P. A. Henkart, *Biochim. Biophys. Acta*, 1988, **939**, 459–466.
- 70 J. P. Crow, *Nitric Oxide*, 1997, **1**, 145–157.
- 71 Y. Qin, M. Lu and X. G. Gong, *Cell Biol. Int.*, 2008, **32**, 224–228.
- 72 L. Yuan, L. Wang, B. K. Agrawalla, S. J. Park, H. Zhu, B. Sivaraman, J. Peng, Q. H. Xu and Y. T. Chang, *J. Am. Chem. Soc.*, 2015, **137**, 5930–5938.
- 73 A. Budnjo, S. Narawane, C. Grauffel, A. S. Schillinger, T. Fossen, N. Reuter and B. E. Haug, *J. Med. Chem.*, 2014, **57**, 9396–9408.
- 74 W. C. Groutas, D. Dou and K. R. Alliston, *Expert Opin. Ther. Pat.*, 2011, **21**, 339–354.
- 75 A. Parks, X. Charest-Morin, M. Boivin-Welch, J. Bouthillier and F. Marceau, *PeerJ*, 2015, **3**, e1314.
- 76 A. T. Sumner, *Histochemistry*, 1986, **84**, 566–574.
- 77 P. Huang, Y. Zou, X. Z. Zhong, Q. Cao, K. Zhao, M. X. Zhu, R. Murrell-Lagnado and X. P. Dong, *J. Biol. Chem.*, 2014, **289**, 17658–17667.
- 78 T. Sasaki, S. Lian, J. Qi, P. E. Bayliss, C. E. Carr, J. L. Johnson, S. Guha, P. Kobler, S. D. Catz, M. Gill, K. Jia, D. J. Klionsky and S. Kishi, *PLoS Genet.*, 2014, **10**, e1004409.
- 79 E. Dona, J. D. Barry, G. Valentin, C. Quirin, A. Khmelinskii, A. Kunze, S. Durdu, L. R. Newton, A. Fernandez-Minan, W. Huber, M. Knop and D. Gilmour, *Nature*, 2013, **503**, 285–289.
- 80 I. Vermes and C. Haanen, *Adv. Clin. Chem.*, 1994, **31**, 177–246.
- 81 J. A. Udovich, D. G. Besselsen and A. F. Gmitro, *J. Microsc.*, 2009, **234**, 124–129.
- 82 T. J. van Ham, J. Mapes, D. Kokel and R. T. Peterson, *FASEB J.*, 2010, **24**, 4336–4342.
- 83 B. Tucker and M. Lardelli, *Zebrafish*, 2007, **4**, 113–116.
- 84 M. Poot, Y. Z. Zhang, J. A. Kramer, K. S. Wells, L. J. Jones, D. K. Hanzel, A. G. Lugade, V. L. Singer and R. P. Haugland, *J. Histochem. Cytochem.*, 1996, **44**, 1363–1372.
- 85 X. Wang, H. Fang, Z. Huang, W. Shang, T. Hou, A. Cheng and H. Cheng, *J. Mol. Med.*, 2013, **91**, 917–927.
- 86 I. D. Trayner, A. P. Rayner, G. E. Freeman and F. Farzaneh, *J. Immunol. Methods*, 1995, **186**, 275–284.
- 87 J. P. Crow, *Nitric Oxide*, 1997, **1**, 145–157.
- 88 Y. Koide, Y. Urano, K. Hanaoka, T. Terai and T. Nagano, *J. Am. Chem. Soc.*, 2011, **133**, 5680–5682.
- 89 B. J. Bain, in *Dacie and Lewis Practical Haematology*, ed. B. J. Bain, I. Bates and M. A. Laffan, Elsevier, 12th edn, 2017.
- 90 S. Bedouhene, F. Moulti-Mati, M. Hurtado-Nedelec, P. M. Dang and J. El-Benna, *Am. J. Blood Res.*, 2017, **7**, 41–48.
- 91 G. Lauter, I. Soll and G. Hauptmann, *Methods Mol. Biol.*, 2014, **1082**, 175–185.
- 92 S. Kossodo, J. Zhang, K. Groves, G. J. Cuneo, E. Handy, J. Morin, J. Delaney, W. Yared, M. Rajopadhye and J. D. Peterson, *Int. J. Mol. Imaging*, 2011, **2011**, 581406.
- 93 P. Kasperkiewicz, Y. Altman, M. D'Angelo, G. S. Salvesen and M. Drag, *J. Am. Chem. Soc.*, 2017, **139**, 10115–10125.
- 94 M. Westerfield, *The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio)*, University of Oregon Press, 1995.
- 95 V. Monceaux, C. Chiche-Lapierre, C. Chaput, V. Witko-Sarsat, M. C. Prevost, C. T. Taylor, M. N. Ungeheuer, P. J. Sansonetti and B. S. Marteyn, *Blood*, 2016, **128**, 993–1002.

